Physician profile
Grady M Wick
NPI 1659575108
$2,815.26
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $82.22 · 2021: $259 · 2022: $628 · 2023: $611 · 2024: $468 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $22.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.76 |
| Education | $22.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $508.74 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $430.58 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $378.85 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $300.54 | 2022-2024 | |
| Amgen INC. | $275.81 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Mallinckrodt Hospital Products INC. | $161.09 | 2024-2025 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $131.38 | 2019-2021 | |
| Travere Therapeutics, INC. | $115.53 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $72.27 | 2022-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $52.19 | 2024 | |
| Aurinia Pharma U.S., INC. | $49.44 | 2022-2023 | Lupkynis |
| Nxstage Medical, INC. | $46.80 | 2019 | |
| Akebia Therapeutics INC | $40.23 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.51 | 2022-2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $38.77 | 2022-2023 | Rayaldee |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $32.16 | 2019 | |
| Daiichi Sankyo INC. | $24.84 | 2023 | Injectafer |
| Pharmacosmos Therapeutics INC. | $23.01 | 2022 | |
| Fresenius USA Marketing, INC. | $22.70 | 2024 | Velphoro |
| Ultragenyx Pharmaceutical INC. | $22.10 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2023 | Jardiance |
| Amag Pharmaceuticals, INC. | $16.67 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grady Wick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.